Filipa Quintela Vieira

Filipa Quintela Vieira

Auto-generated profile, based on publicly available information

Filipa Quintela Vieira

Research Centre in Health and Environment (CISA), School of Health (ESS), Polytechnic Institute of Porto (P.PORTO), 4200-072 Porto, Portugal

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2015 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
PCPedro Costa-Pinheiro
Pedro Costa-Pinheiro
JRJoao Ramalho-Carvalho
Joao Ramalho-Carvalho
FVFilipa Quintela Vieira
Filipa Quintela Vieira
JTJorge Torres-Ferreira
Jorge Torres-Ferreira
JOJorge Oliveira
Jorge Oliveira
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Prostate cancer (PCa), a highly incident and heterogeneous malignancy, mostly affects men from developed countries. Increased knowledge of the biological mechanisms underlying PCa onset and progression are critical for improved clinical management. MicroRNAs (miRNAs) deregulation is common in human cancers, and understanding how it impacts in PCa is of major importance. MiRNAs are mostly downregulated in cancer, although some are overexpressed, playing a critical role in tumor initiation and progression. We aimed to identify miRNAs overexpressed in PCa and subsequently determine its impact in tumorigenesis. MicroRNA expression profiling in primary PCa and morphological normal prostate (MNPT) tissues identified 17 miRNAs significantly overexpressed in PCa. Expression of three miRNAs, not previously associated with PCa, was subsequently assessed in large independent sets of primary tumors, in which miR-182 and miR-375 were validated, but not miR-32. Significantly higher expression levels of miR-375 were depicted in patients with higher Gleason score and more advanced pathological stage, as well as with regional lymph nodes metastases. Forced expression of miR-375 in PC-3 cells, which display the lowest miR-375 levels among PCa cell lines, increased apoptosis and reduced invasion ability and cell viability. Intriguingly, in 22Rv1 cells, which displayed the highest miR-375 expression, knockdown experiments also attenuated the malignant phenotype. Gene ontology analysis implicated miR-375 in several key pathways deregulated in PCa, including cell cycle and cell differentiation. Moreover, CCND2 was identified as putative miR-375 target in PCa, confirmed by luciferase assay. A dual role for miR-375 in prostate cancer progression is suggested, highlighting the importance of cellular context on microRNA targeting.

7 November 2013 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
FVFilipa Quintela Vieira
Filipa Quintela Vieira
PCPedro Costa-Pinheiro
Pedro Costa-Pinheiro
JRJoao Ramalho-Carvalho
Joao Ramalho-Carvalho
APAndreia Pereira
Andreia Pereira
FMFrancisco Duarte Menezes
Francisco Duarte Menezes
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Prostate cancer (PCa), a leading cause of cancer-related morbidity and mortality, arises through the acquisition of genetic and epigenetic alterations. Deregulation of histone methyltransferases (HMTs) or demethylases (HDMs) has been associated with PCa development and progression. However, the precise influence of altered HMTs or HDMs expression and respective histone marks in PCa onset and progression remains largely unknown. To clarify the role of HMTs and HDMs in prostate carcinogenesis, expression levels of 37 HMTs and 20 HDMs were assessed in normal prostate and PCa tissue samples by RT-qPCR.SMYD3,SUV39H2,PRMT6,KDM5A, andKDM6Awere upregulated, whereasKMT2A-E (MLL1-5)andKDM4Bwere downregulated in PCa, compared with normal prostate tissues. Remarkably,PRMT6was the histone modifier that best discriminated normal from tumorous tissue samples. Interestingly,EZH2andSMYD3expression levels significantly correlated with less differentiated and more aggressive tumors. Remarkably,SMYD3expression levels were of independent prognostic value for the prediction of disease-specific survival of PCa patients with clinically localized disease submitted to radical prostatectomy. We concluded that expression profiling of HMTs and HDMs, especiallySMYD3, might be of clinical usefulness for the assessment of PCa patients and assist in pre-therapeutic decision-making.

25 April 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
FVFilipa Quintela Vieira
Filipa Quintela Vieira
PCPedro Costa-Pinheiro
Pedro Costa-Pinheiro
DADiogo Almeida-Rios
Diogo Almeida-Rios
IGInês Graça
Inês Graça
SMSara Monteiro-Reis
Sara Monteiro-Reis
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3 SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3

19 October 2015 in Epigenetics
Verified
Journal Article
Open access
APAna Sílvia Pires-Luís
Ana Sílvia Pires-Luís
MVMárcia Vieira-Coimbra
Márcia Vieira-Coimbra
FVFilipa Quintela Vieira
Filipa Quintela Vieira
PCPedro Costa-Pinheiro
Pedro Costa-Pinheiro
RSRui Silva-Santos
Rui Silva-Santos
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Renal cell tumors (RCTs) are the most lethal of the common urological cancers. The widespread use of imaging entailed an increased detection of small renal masses, emphasizing the need for accurate distinction between benign and malignant RCTs, which is critical for adequate therapeutic management. Histone methylation has been implicated in renal tumorigenesis, but its potential clinical value as RCT biomarker remains mostly unexplored. Hence, the main goal of this study was to identify differentially expressed histone methyltransferases (HMTs) and histone demethylases (HDMs) that might prove useful for RCT diagnosis and prognostication, emphasizing the discrimination between oncocytoma (a benign tumor) and renal cell carcinoma (RCC), especially the chromophobe subtype (chRCC). We found that the expression levels of 3 genes—SMYD2, SETD3, and NO66—was significantly altered in a set of RCTs, which was further validated in a large independent cohort. Higher expression levels were found in RCTs compared to normal renal tissues (RNTs) and in chRCCs comparatively to oncocytomas. SMYD2 and SETD3 mRNA levels correlated with protein expression assessed by immunohistochemistry. SMYD2 transcript levels discriminated RCTs from RNT, with 82.1% sensitivity and 100% specificity [area under curve (AUC) = 0.959], and distinguished chRCCs from oncocytomas, with 71.0% sensitivity and 73.3% specificity (AUC = 0.784). Low expression levels of SMYD2, SETD3, and NO66 were significantly associated with shorter disease-specific and disease-free survival, especially in patients with non-organ confined tumors. We conclude that expression of selected HMTs and HDMs might constitute novel biomarkers to assist in RCT diagnosis and assessment of tumor aggressiveness.

1 May 2013 in Epigenetics
Verified
Journal Article
Open access
PDF file
ESElsa J. Sousa
Elsa J. Sousa
IGInês Graça
Inês Graça
TBTiago Baptista
Tiago Baptista
FVFilipa Q. Vieira
Filipa Q. Vieira
CPCarlos Palmeira
Carlos Palmeira
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Prostate cancer (PCa) is one of the most incident malignancies worldwide. Although efficient therapy is available for early-stage PCa, treatment of advanced disease is mainly ineffective and remains a clinical challenge. microRNA (miRNA) dysregulation is associated with PCa development and progression. In fact, several studies have reported a widespread downregulation of miRNAs in PCa, which highlights the importance of studying compounds capable of restoring the global miRNA expression. The main aim of this study was to define the usefulness of enoxacin as an anti-tumoral agent in PCa, due to its ability to induce miRNA biogenesis in a TRBP-mediated manner. Using a panel of five PCa cell lines, we observed that all of them were wild type for the TARBP2 gene and expressed TRBP protein. Furthermore, primary prostate carcinomas displayed normal levels of TRBP protein. Remarkably, enoxacin was able to decrease cell viability, induce apoptosis, cause cell cycle arrest, and inhibit the invasiveness of cell lines. Enoxacin was also effective in restoring the global expression of miRNAs. This study is the first to show that PCa cells are highly responsive to the anti-tumoral effects of enoxacin. Therefore, enoxacin constitutes a promising therapeutic agent for PCa.

15 June 2016 in Oncotarget
Verified
Journal Article
Open access
DADiogo Almeida-Rios
Diogo Almeida-Rios
IGInês Graça
Inês Graça
FVFilipa Quintela Vieira
Filipa Quintela Vieira
JRJoao Ramalho-Carvalho
Joao Ramalho-Carvalho
EPEva Pereira-Silva
Eva Pereira-Silva
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer